A multicentre, randomised trial of radioimmunotherapy with labetuzumab I-131, compared with post-operative chemotherapy or labetuzumab I-131 in combination with chemotherapy, in patients with liver metastases from colorectal cancer.
Phase of Trial: Phase II
Latest Information Update: 21 May 2008
At a glance
- Drugs Labetuzumab I 131 (Primary) ; Antineoplastics
- Indications Cancer metastases; Colorectal cancer
- Focus Therapeutic Use
- 25 Jun 2007 New trial record.